Ratings by Piper Sandler (Kelsey Goodwin)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 8/7/2026 | CG Oncology | CGON | Maintain | Overweight (N/A) |
|
Details | ||
| 8/5/2026 | Obsidian Therapeutics | OBX | New Coverage | Overweight (N/A) |
0.04 (16.82) |
41950% | Details | |
| 6/9/2026 | Nuvalent | NUVL | Downgrade | Neutral (Overweight) |
88.49 (123.96) |
40.08% | Details | |
| 5/27/2026 | LeonaBio | LONA | New Coverage | Overweight (N/A) |
10.33 (7.56) |
-26.82% | Details | |
| 5/15/2026 | Tango Therapeutics Inc. | TNGX | Downgrade | Neutral (Overweight) |
25.51 (22.52) |
-11.72% | Details | |
| 5/8/2026 | Janux Therapeutics | JANX | Maintain | Overweight (N/A) |
|
Details | ||
| 5/7/2026 | Revolution | RVMD | Maintain | Overweight (N/A) |
|
Details | ||
| 5/1/2026 | Summit Therapeutics plc | SMMT | Maintain | Neutral (N/A) |
|
Details | ||
| 3/24/2026 | Relmada Therapeutics Inc | RLMD | New Coverage | Overweight (N/A) |
6.07 (4.43) |
-27.02% | Details | |
| 3/13/2026 | Erasca Inc | ERAS | Maintain | Overweight (N/A) |
|
Details | ||
| 3/6/2026 | Day One Biopharmaceuticals | DAWN | Downgrade | Neutral (Overweight) |
12.78 (21.53) |
68.47% | Details | |
| 2/26/2026 | Revolution | RVMD | Maintain | Overweight (N/A) |
|
Details | ||
| 1/16/2026 | Tango Therapeutics Inc. | TNGX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/16/2026 | Janux Therapeutics | JANX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/16/2026 | Erasca Inc | ERAS | Maintain | Overweight (N/A) |
|
Details | ||
| 1/16/2026 | CG Oncology | CGON | Maintain | Overweight (N/A) |
|
Details | ||
| 1/16/2026 | Black Diamond Therapeutics | BDTX | Maintain | Overweight (N/A) |
|
Details | ||
| 1/7/2026 | Protera Therapeutics | TARA | New Coverage | Overweight (N/A) |
5.39 (3.94) |
-26.9% | Details | |
| 1/7/2026 | ORIC Pharmaceuticals | ORIC | New Coverage | Overweight (N/A) |
8.15 (12.86) |
57.79% | Details | |
| 1/7/2026 | Olema Pharmaceuticals | OLMA | New Coverage | Overweight (N/A) |
25.10 (10.75) |
-57.17% | Details | |
| 1/7/2026 | Erasca Inc | ERAS | New Coverage | Overweight (N/A) |
3.49 (16.19) |
363.9% | Details | |
| 11/17/2025 | Black Diamond Therapeutics | BDTX | New Coverage | Overweight (N/A) |
4.01 (2.12) |
-47.13% | Details | |
| 11/5/2025 | Day One Biopharmaceuticals | DAWN | Maintain | Overweight (N/A) |
|
Details | ||
| 10/27/2025 | Nuvalent | NUVL | Maintain | Overweight (N/A) |
|
Details | ||
| 8/19/2025 | Nuvalent | NUVL | New Coverage | Overweight (N/A) |
75.01 (88.49) |
17.97% | Details | |
| 8/19/2025 | Tango Therapeutics Inc. | TNGX | New Coverage | Overweight (N/A) |
6.77 (25.51) |
276.81% | Details | |
| 8/19/2025 | UroGen Pharma | URGN | New Coverage | Overweight (N/A) |
19.71 (44.09) |
123.69% | Details | |
| 8/19/2025 | Summit Therapeutics plc | SMMT | New Coverage | Neutral (N/A) |
26.69 (17.61) |
-34.02% | Details | |
| 8/19/2025 | Revolution | RVMD | New Coverage | Overweight (N/A) |
36.32 (210.02) |
478.25% | Details | |
| 8/19/2025 | Janux Therapeutics | JANX | New Coverage | Overweight (N/A) |
25.11 (20.24) |
-19.39% | Details | |
| 8/19/2025 | Day One Biopharmaceuticals | DAWN | New Coverage | Overweight (N/A) |
52.88 (12.78) |
-75.83% | Details | |
| 8/19/2025 | CG Oncology | CGON | New Coverage | Overweight (N/A) |
25.70 (74.67) |
190.54% | Details | |
| 8/19/2025 | Bicara Therapeutics Inc | BCAX | New Coverage | Overweight (N/A) |
11.64 (23.17) |
99.05% | Details |
